BiotechTubeBiotechTube
Home/Genprex/Rodney Varner
RV

Rodney Varner

Chairman, President & Chief Executive Officer

Genprex

Therapeutic Areas

OncologyLung Cancer

Genprex Pipeline

DrugIndicationPhase
Reqorsa® (quaratusugene ozeplasmid) + Tagrisso® (osimertinib)Non-Small Cell Lung Cancer (NSCLC) with EGFR mutations post-Tagrisso failurePhase 1/2
Reqorsa® (quaratusugene ozeplasmid) + Tecentriq® (atezolizumab)Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Phase 1/2
Reqorsa® (quaratusugene ozeplasmid) + Keytruda® (pembrolizumab)Non-Small Cell Lung Cancer (NSCLC)Phase 1/2
Reqorsa® + other TKIsVarious CancersResearch
GPX-002Undisclosed Solid TumorResearch

Leadership Team at Genprex

RC
Ryan Confer
Chief Financial Officer
MB
Mark Berger
Chief Medical Officer
JL
Julien L. Pham
Chief Operating Officer
MT
Michael T. Redman
Executive Vice President, Corporate Development & Strategy
JD
J. David Enloe, Jr.
Director
BL
Brent Longnecker
Director
View full Genprex profile